HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) and maintained a price target of $74.
June 04, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on SpringWorks Therapeutics and maintained a price target of $74, indicating confidence in the company's future performance.
The reiteration of a Buy rating and a maintained price target of $74 by HC Wainwright & Co. suggests strong confidence in SpringWorks Therapeutics' future performance. This is likely to positively impact the stock price in the short term as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100